Rapid Micro Biosystems (RPID) Total Debt (2020 - 2026)

Rapid Micro Biosystems (RPID) posted Total Debt of $19.1 million for Q1 2026, up 0.8% sequentially from $18.9 million in Q4 2025.

Rapid Micro Biosystems (RPID) Total Debt (2020 - 2026) Analysis & Trends

Rapid Micro Biosystems has reported Total Debt for 4 years, with the latest figure at $19.1 million in Q1 2026.

Quarterly Total Debt changed N/A year-over-year to $19.1 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $19.1 million (changed N/A YoY) and the FY2025 annual result came in at $18.9 million, changed N/A from the prior year.
Total Debt grew to $19.1 million in Q1 2026 per RPID's latest filing, from $18.9 million in the prior quarter.
Over five years, Total Debt peaked at $19.1 million in Q1 2026 and troughed at $18.8 million in Q3 2025.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Total Debt (Qtr)
1	Abbott Laboratories	199.61 Bn	194.01 Bn	7.27 Bn	32.61 Bn
2	Stryker	127.81 Bn	124.34 Bn	4.50 Bn	14.94 Bn
3	Medtronic	119.04 Bn	109.82 Bn	6.41 Bn	27.96 Bn
4	Boston Scientific	73.68 Bn	73.14 Bn	3.85 Bn	12.62 Bn
5	Edwards Lifesciences	51.96 Bn	47.71 Bn	1.35 Bn	598.70 Mn
6	Dexcom	34.36 Bn	32.41 Bn	830.00 Mn	-
7	GE HealthCare Technologies	33.83 Bn	31.72 Bn	2.18 Bn	10.10 Bn
8	Koninklijke Philips	26.36 Bn	23.04 Bn	4.55 Bn	8.68 Bn
9	Steris	23.06 Bn	22.58 Bn	684.20 Mn	1.89 Bn
10	Rapid Micro Biosystems	80.50 Mn	60.73 Mn	1.21 Mn	19.14 Mn

Download Data